Skip to content
Log in

Author

Nermin Samir

View on Semantic Scholar

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Jul 2026

FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches

FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML); mutations within FLT3, specifically ITD lesions and TKD point mutations, promote proliferation and are associated with poor prognosis. Although FLT3 inhibition is central to AML therapy, resistance, particularly via D835 activation-loop variants and the F691L gatekeeper substitution, limits durability. Among the major therapeutic classes, type I inhibitors bind the active (DFG-in) conformation, whereas type II inhibitors stabilize the inactive (DFG-out) state. In contrast, irreversible covalent inhibitors target reactive cysteine residues within the kinase domain. Collectively, these approaches represent complementary therapeutic strategies with distinct resistance liabilities and structural design considerations. This review integrates structural biology with medicinal-chemistry evidence across type I, type II, irreversible, and dual-modality FLT3 inhibitors, analyzing how hinge contacts, back-pocket occupancy, and warhead placement govern activity across wild-type and mutant FLT3. We map resistance-defining residues (e.g. F691, D835, N676, N701) and design tactics to preserve potency against resistant variants. We also summarize combination therapy that augments selective FLT3 blockade and outline PROTAC approaches that induce FLT3 degradation, positioning these modalities as alternatives when single-molecule polypharmacology is constrained. Finally, we catalogue dual-target FLT3 chemotypes, highlighting examples that retain activity against F691L and D835 in cellular systems and xenografts. Overall, this review provides a section-by-section guide covering FLT3 structure and mutation hotspots, analyses of type I, type II, and irreversible inhibitors, dual-modality designs, combinations, PROTACs, and future perspectives. It links binding mode, covalent engagement, and second-target selection to recurrent resistance biology to guide more resilient FLT3-targeted therapies for high-risk AML.

Fatma M Elmenier, Eman M. E. Dokla, Nermin Samir et al. · 0 citations
Review Open access Jul 2026

Unlocking new antimicrobial leads in the last decade: exploring quinolin-2-one based hybrids' synthesis, action, SAR, and challenges in tackling antimicrobial resistance.

The rapid emergence of antimicrobial resistance (AMR) posed a major global health threat and created an urgent need for new broad-spectrum antimicrobial agents. The quinolin-2-one scaffold emerged as a privileged structural motif in medicinal chemistry because it exhibited promising activity against a wide range of bacterial and fungal pathogens. Continuous optimization of this scaffold remained essential to address the increasing burden of resistance. This review summarized recent advances in quinolin-2-one derivatives reported from 2015 to 2025. It systematically examined synthetic approaches and revealed a growing shift toward greener and more sustainable methodologies. The review also analyzed the structure-activity relationships that governed antimicrobial potency, integrated findings from biological evaluations, discussed proposed mechanisms of action, including inhibition of DNA topoisomerases and disruption of cell wall biosynthesis, and assessed the available toxicity data for the reported compounds. Advantages, disadvantages and future perspectives Quinolin-2-one derivatives demonstrated considerable therapeutic promise as versatile antimicrobial scaffolds. However, current studies revealed several limitations, including poor aqueous solubility, insufficient preclinical ADMET characterization, and limited in vivo validation. Future investigations should address these pharmacokinetic and toxicological limitations to support the rational design of next-generation quinolin-2-one hybrids and improve their potential for clinical translation.

M. Khattab, Mai I Shahin, A. Taher et al. · 0 citations